Could a new drug keep HIV in check without daily pills?

This study tests whether baricitinib, an anti-inflammatory drug, can keep HIV under control after participants stop their usual antiretroviral therapy (ART). Twenty people with well-controlled HIV will take baricitinib alongside ART for 26 weeks, then continue baricitinib alone for up to 24 weeks to see if the virus stays suppressed. The goal is to delay or prevent viral rebound, but lifelong medication is still expected, so this is not a cure.